Glaxo CEO Witty to focus on 'key franchises' instead of smaller money makers

When the asset swap between GlaxoSmithKline, Novartis and Eli Lilly goes through in the first part of next year, each company says it will generate a larger portion of its overall revenue from its key focus areas...